2. Search Result
Search Result
Results for "

thrombin generation

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

2

Fluorescent Dyes

6

Peptides

3

Inhibitory Antibodies

1

Natural
Products

8

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0019
    Z-Gly-Gly-Arg-AMC
    10+ Cited Publications

    		 Fluorescent Dye Thrombin Cardiovascular Disease
    Z-Gly-Gly-Arg-AMC is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm) .
    Z-Gly-Gly-Arg-AMC
  • HY-132587
    Fitusiran

    ALN-AT3SC; SAR439774

    		 Factor Xa Small Interfering RNA (siRNA) Thrombin Cardiovascular Disease
    Fitusiran (ALN-AT3SC) is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran can be used in hemophilia-related research .
    Fitusiran
  • HY-P0019A
    Z-Gly-Gly-Arg-AMC acetate
    10+ Cited Publications

    		 Fluorescent Dye Thrombin Others
    Z-Gly-Gly-Arg-AMC acetate is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm) .
    Z-Gly-Gly-Arg-AMC acetate
  • HY-132587A
    Fitusiran sodium

    ALN-AT3SC sodium; SAR439774 sodium

    		 Factor Xa Small Interfering RNA (siRNA) Thrombin Cardiovascular Disease
    Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .
    Fitusiran sodium
  • HY-P99794
    Osocimab

    BAY 1213790

    		 Factor Xa Cardiovascular Disease
    Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
    Osocimab
  • HY-P3009
    Bovine Factor Xa

    		Factor Xa Cardiovascular Disease
    Bovine Factor Xa, a trypsin-like serine protease, is an important player in the coagulation cascade responsible for thrombin generation .
    Bovine Factor Xa
  • HY-150224
    GalNAc unconjugated/naked Fitusiran sodium

    		Small Interfering RNA (siRNA) Factor Xa Others
    GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .
    GalNAc unconjugated/naked Fitusiran sodium
  • HY-N2082
    Isorhamnetin 3-O-galactoside
    1 Publications Verification

    Cacticin

    		 Thrombin COX ERK JNK Factor Xa Cardiovascular Disease Inflammation/Immunology
    Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .
    Isorhamnetin 3-O-galactoside
  • HY-112865
    Octocog alfa

    ADVATE; BAY 81-8973; Kovaltry

    		 Factor VIII Cardiovascular Disease
    Octocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a standard half-length recombinant coagulation factor FVIII replacement therapy that also functions as a thrombin generation modulator. Octocog alfa regulates thrombin generation-related parameters in vitro and is used in studies related to severe hemophilia A .
    Octocog alfa
  • HY-153480A
    ARC19499 sodium
    1 Publications Verification

    BAX499 sodium

    		 Factor Xa Factor VIIa Tissue Factor Pathway Inhibitor (TFPI) Others
    ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499 sodium
  • HY-P5875A
    P4pal10 TFA

    		Protease Activated Receptor (PAR) Cardiovascular Disease Inflammation/Immunology
    P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
    P4pal10 TFA
  • HY-153480
    ARC19499

    BAX499

    		 Factor Xa Factor VIIa Tissue Factor Pathway Inhibitor (TFPI) Others
    ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.
    ARC19499
  • HY-166257
    Lyso-sulfatide (bovine)

    Psychosine 3′-O-sulfate; Psychosine 3′-sulfate

    		 Biochemical Assay Reagents Factor Xa Metabolic Disease
    Lyso-sulfatide (bovine) is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions .
    Lyso-sulfatide (bovine)
  • HY-P991029
    Sutacimig

    HMB-001

    		 Thrombin Ser/Thr Protease TREM receptor Cardiovascular Disease
    Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .
    Sutacimig
  • HY-14654B
    Aspirin DL-lysine

    Acetylsalicylic acid DL-lysine; ASA DL-lysine

    		 COX NF-κB p38 MAPK Cardiovascular Disease Others Inflammation/Immunology
    Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .
    Aspirin DL-lysine
  • HY-19674
    SSR182289

    SSR182289A free base

    		 Thrombin Cardiovascular Disease
    SSR182289 (SSR182289A free base) is a selective and potent orally active thrombin inhibitor. SSR182289 competitively and selectivity inhibits human thrombin (Ki=0.031 μM). SSR182289 demonstrates anticoagulant activity in vitro (thrombin time EC100=96 nM) and inhibits tissue factor-induced thrombin generation (IC50=0.15 μM) in human plasma. SSR182289 inhibits thrombin-induced aggregation of human platelets (IC50=32 nM), but has no effect on aggregation induced by other platelet agonists .
    SSR182289
  • HY-P0019B
    Z-Gly-Gly-Arg-AMC TFA

    		Fluorescent Dye Thrombin Others
    Z-Gly-Gly-Arg-AMC TFA is the TFA salt form of Z-Gly-Gly-Arg-AMC (HY-P0019). Z-Gly-Gly-Arg-AMC TFA is a thrombin-specific fluorogenic substrate for testing of thrombin generation in PRP and platelet-poor plasma (PPP) (Ex/Em = 390/480 nm) .
    Z-Gly-Gly-Arg-AMC TFA
  • HY-P5202
    H-Gly-Gly-Arg-AMC

    		Amino Acid Derivatives Others
    H-Gly-Gly-Arg-AMC is a fluorogenic peptidyl-AMC substrate containing C-terminal 7-amino-4-methylcoumarin (AMC). H-Gly-Gly-Arg-AMC is a suitable for monitoring continuous thrombin generation (TGT) .
    H-Gly-Gly-Arg-AMC
  • HY-P991213
    Nonacog gamma

    Rixubis

    		 Factor XI Cardiovascular Disease
    Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .
    Nonacog gamma
  • HY-P5875
    P4pal10

    		Protease Activated Receptor (PAR) Cardiovascular Disease Inflammation/Immunology
    P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .
    P4pal10
  • HY-165180
    Lyso-sulfatide (bovine) sodium

    Psychosine 3′-O-sulfate sodium; Psychosine 3′-sulfate sodium

    		 Biochemical Assay Reagents Factor Xa Metabolic Disease
    Lyso-sulfatide (bovine) sodium is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) sodium binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) sodium serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions .
    Lyso-sulfatide (bovine) sodium
  • HY-19517
    R1663

    		Endogenous Metabolite Cardiovascular Disease
    R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
    R1663
  • HY-132587C
    Fitusiran sodium scrambled negative control

    		Small Interfering RNA (siRNA) Factor Xa Thrombin Cardiovascular Disease
    Fitusiran sodium scrambled negative control is the sequence scrambled negative control of Fitusiran sodium. Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .
    Fitusiran sodium scrambled negative control
  • HY-132587D
    FAM labled Fitusiran sodium

    		Fluorescent Dye Factor Xa Small Interfering RNA (siRNA) Thrombin Cardiovascular Disease
    FAM labled Fitusiran sodiumis a FAM labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .
    FAM labled Fitusiran sodium
  • HY-132587E
    Cy3 labled Fitusiran sodium

    		Fluorescent Dye Small Interfering RNA (siRNA) Factor Xa Thrombin Cardiovascular Disease
    Cy3 labled Fitusiran sodium is a Cy3 labled Fitusiran sodium (HY-132587A). Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research .
    Cy3 labled Fitusiran sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: